来特莫韦预防造血干细胞移植后青少年患者巨细胞病毒感染。
Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.
机构信息
Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Pharmacy, Maine Medical Center, Portland, Maine, USA.
出版信息
J Pediatric Infect Dis Soc. 2022 Jul 21;11(7):337-340. doi: 10.1093/jpids/piac017.
Abstract
There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.
摘要
有关更昔洛韦作为小于 18 岁患者的原发性巨细胞病毒（CMV）预防的资料有限。我们报告了 9 例接受更昔洛韦治疗的造血细胞移植后的青少年患者。在使用更昔洛韦的患者中没有发生有临床意义的 CMV。更昔洛韦在预防 CMV 感染方面具有良好的耐受性和疗效。
相似文献
1
Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.来特莫韦预防造血干细胞移植后青少年患者巨细胞病毒感染。
J Pediatric Infect Dis Soc. 2022 Jul 21;11(7):337-340. doi: 10.1093/jpids/piac017.
2
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
3
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.造血干细胞移植受者在二次莱曲莫韦预防治疗期间出现耐药巨细胞病毒的快速突破。
BMC Infect Dis. 2019 May 8;19(1):388. doi: 10.1186/s12879-019-4016-1.
4
Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.来特莫韦在异基因造血干细胞移植后预防巨细胞病毒感染中的作用。
Curr Opin Infect Dis. 2018 Aug;31(4):286-291. doi: 10.1097/QCO.0000000000000459.
5
Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.异基因造血干细胞移植患者使用来特莫韦的真实世界安全性和有效性：日本上市后监测的最终结果。
Clin Drug Investig. 2024 Jul;44(7):527-540. doi: 10.1007/s40261-024-01376-w. Epub 2024 Jun 27.
6
Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.来特莫韦用于异基因造血干细胞移植受者预防巨细胞病毒感染
Drugs Today (Barc). 2018 Jun;54(6):361-368. doi: 10.1358/dot.2018.54.6.2833982.
7
Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.来特莫韦用于儿童造血干细胞移植受者耐巨细胞病毒挽救治疗的研究
J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):486-489. doi: 10.1093/jpids/piz050.
8
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience.来特莫韦作为异基因造血细胞移植后巨细胞病毒感染的二级预防：单中心经验。
Eur J Haematol. 2024 Oct;113(4):477-484. doi: 10.1111/ejh.14258. Epub 2024 Jun 21.
9
Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.来特莫韦预防期间的巨细胞病毒突破和耐药性。
Bone Marrow Transplant. 2023 Apr;58(4):430-436. doi: 10.1038/s41409-023-01920-w. Epub 2023 Jan 24.
10
Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.对于移植物抗宿主病患者，在第 100 天之后延长来特莫韦给药时间，对于 CMV 预防是有效的。
Transpl Infect Dis. 2021 Apr;23(2):e13487. doi: 10.1111/tid.13487. Epub 2020 Oct 27.
引用本文的文献
1
Real-world efficacy and safety of letermovir versus ganciclovir prophylaxis in adolescent patients undergoing allogenic hematopoietic stem cell transplantation: a single center observational study.来特莫韦与更昔洛韦预防在接受异基因造血干细胞移植的青少年患者中的真实世界疗效和安全性：一项单中心观察性研究
Front Cell Infect Microbiol. 2025 Jun 3;15:1558637. doi: 10.3389/fcimb.2025.1558637. eCollection 2025.
2
Cytomegalovirus Triplex vaccine in pediatric hematopoietic stem cell transplant patients at high risk for cytomegalovirus complications: evaluation of vaccine safety, immunogenicity and impact on viremia requiring antivirals.巨细胞病毒三联疫苗用于有巨细胞病毒并发症高风险的儿科造血干细胞移植患者：疫苗安全性、免疫原性及对需要抗病毒治疗的病毒血症影响的评估
Haematologica. 2024 Jul 1;109(7):2303-2308. doi: 10.3324/haematol.2023.284256.
3
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients.目前和新兴的抗病毒药物在儿科移植受者巨细胞病毒预防和治疗中的应用。
J Pediatric Infect Dis Soc. 2024 Feb 28;13(Supplement_1):S14-S21. doi: 10.1093/jpids/piad059.
4
Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study.来特莫韦有效预防造血干细胞移植后再生障碍性贫血患者的巨细胞病毒感染：一项真实世界回顾性队列研究。
Infect Dis Ther. 2024 Feb;13(2):345-359. doi: 10.1007/s40121-024-00917-2. Epub 2024 Jan 24.
5
Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染的疗效和安全性。
Blood Sci. 2024 Jan 10;6(1):e00178. doi: 10.1097/BS9.0000000000000178. eCollection 2024 Jan.
6
Cytomegalovirus in children undergoing haematopoietic stem cell transplantation: a diagnostic and therapeutic approach to antiviral resistance.接受造血干细胞移植儿童的巨细胞病毒感染：抗病毒耐药性的诊断与治疗方法
Front Pediatr. 2023 May 30;11:1180392. doi: 10.3389/fped.2023.1180392. eCollection 2023.
7
Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review.儿科造血干细胞移植受者中人巨细胞病毒的预防与管理：综述
Front Pediatr. 2022 Nov 23;10:1039938. doi: 10.3389/fped.2022.1039938. eCollection 2022.
本文引用的文献
1
How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后 CMV 再激活的治疗策略
Blood. 2020 May 7;135(19):1619-1629. doi: 10.1182/blood.2019000956.
2
Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.人巨细胞病毒在异基因造血干细胞移植受者中的潜伏与激活
Front Microbiol. 2019 May 28;10:1186. doi: 10.3389/fmicb.2019.01186. eCollection 2019.
3
Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy.造血干细胞移植后巨细胞病毒感染：现状与未来免疫治疗。
Int J Mol Sci. 2019 May 30;20(11):2666. doi: 10.3390/ijms20112666.
4
Letermovir in paediatric HSCT recipients.来特莫韦用于儿科造血干细胞移植受者。
J Antimicrob Chemother. 2019 Sep 1;74(9):2820-2821. doi: 10.1093/jac/dkz218.
5
Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.异基因造血细胞移植中巨细胞病毒感染的抗病毒预防。
Blood Adv. 2018 Aug 28;2(16):2159-2175. doi: 10.1182/bloodadvances.2018016493.
6
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
7
Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation.巨细胞病毒复发风险患者是谁：聚焦造血细胞移植的当前科学证据综述
Infect Dis Ther. 2018 Mar;7(1):1-16. doi: 10.1007/s40121-017-0180-z. Epub 2017 Dec 4.
8
Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent.来特莫韦治疗人巨细胞病毒感染 抗感染药物
Drugs Future. 2013 May;38(5):291-298. doi: 10.1358/dof.2013.038.05.1946425.
9
Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the inborn errors, infectious diseases and pediatric diseases working parties of EBMT.代表 EBMT 的先天错误、传染病和儿科疾病工作组，对儿科异基因 HSCT 项目中的 CMV 管理进行调查。
Bone Marrow Transplant. 2014 Feb;49(2):276-9. doi: 10.1038/bmt.2013.164. Epub 2013 Oct 28.
10
Cytomegalovirus in hematopoietic stem cell transplant recipients.造血干细胞移植受者巨细胞病毒感染。
Hematol Oncol Clin North Am. 2011 Feb;25(1):151-69. doi: 10.1016/j.hoc.2010.11.011.
Zotero 插件